JW Life Science Corp
KRX:234080
Net Margin
JW Life Science Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| KR |
|
JW Life Science Corp
KRX:234080
|
188.1B KRW |
18%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
723.3B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
402.5B USD |
25%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
204.5B CHF |
14%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
172.2B GBP |
15%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
182.3B CHF |
25%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
35%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
199.6B USD |
26%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
133B USD |
13%
|
JW Life Science Corp
Glance View
JW Life Science Corp. manufactures intravenous fluids. The company is headquartered in Dangjin, Chungcheongnam-Do. The company went IPO on 2016-10-27. The firm is engaged in manufacture of basic IV fluid including water, electrolytes and glucose; nutrient infusion solution including amino acids, lipids, proteins, vitamins and minerals; and special infusion solution, which is used in special cases. The firm is also engaged in manufacture of total parenteral nutrition (TPN) products and others.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on JW Life Science Corp's most recent financial statements, the company has Net Margin of 18.5%.
You don't have any saved screeners yet